Waldencast Prices the Obagi Exit, Not Milk

Summary: Waldencast (WALD) traded at $1.78 on June 1, 2026 after agreeing to sell Obagi Medical for up to $460 million. The market is reacting to founder departures and deal complexity. It is not fully pricing the cash deleveraging math. Using only the disclosed $366 million cash consideration plus the $10 million fixed vendor note, and before giving credit to the adjustable note or earnout, the residual equity value left after repaying about $178 million of senior secured debt implies the remaining Milk Makeup business is being valued at roughly $37 million against $15.2 million of 2025 adjusted EBITDA.

Scope note: this run is explicitly limited to U.S. market focus and long only. I scanned articles/2026-06/week-1/, repo-wide titles, and the mispricing-us-market automation memory before selection. Existing current-week topics excluded include cooper, lululemon, neuronetics, amprius, celcuity, hallador, optimum, marchex, and destination-xl. Creative search lanes used: signed asset divestitures that leave behind mispriced stubs, board-led strategic exits with founder turnover, broken-cap-table biotechs trading near cash, and public takeover headlines already priced through the offer.

Opportunity Ranking

Rank	Idea	Discovery Lane	Why It May Be Best Now	Evidence Freshness	Catalyst Window	Near-Term >5% Move Case	Asymmetry	Main Reason to Reject
1	Long `WALD` common	U.S.-listed special situation / signed asset sale / deleveraging stub	A signed Obagi sale at up to $460 million lets the market re-mark a two-brand platform into a debt-repaid cash stub plus Milk Makeup. The current market cap still leaves little value for the remaining brand.	High: June 1, 2026 sale announcement and June 1 market price reaction.	Days to weeks for cash-math recognition; Q3 2026 for closing.	A move from $1.78 to $1.87 is 5.1%. That can happen if investors rework the stub value using disclosed cash proceeds and debt payoff instead of focusing only on founder exits.	High: debt repayment is explicit, downside is visible, and the residual business is not worthless.	Selected.
2	Long `JSPR` common	U.S. biotech / strategic review / cash shell risk	Jasper launched a strategic-alternatives review on June 1 while holding $14.1 million of cash at March 31 against a micro-cap equity value near cash.	High: June 1 8-K and May 14 Q1 release.	Immediate, but soft.	A move from $0.55 to $0.58 is more than 5% if any financing or process update hits.	Real, but messy.	Rejected because the company explicitly needs additional funding, so dilution can overwhelm the review before a buyer appears.
3	Long `MGM` common	U.S. large-cap event / non-binding bid	IAC proposed $48.30 in cash for MGM on June 1.	High: June 1 filing and same-day trading reaction.	Immediate board-response window.	The stock can move on any board response or topping speculation.	Weak.	Rejected because the stock traded above the headline bid, which means the market already prices either a sweeter deal or low credibility. The simple spread is gone.

Selected opportunity: Long WALD common stock.

Why this one now: It is the cleanest signed arithmetic in the screen. Unlike Jasper, it does not depend on a speculative rescue financing. Unlike MGM, it does not ask the buyer to improve the headline price before the long works. The company has already agreed to sell Obagi, already disclosed the debt paydown plan, and already told the market what Milk Makeup produced in 2025.

Why it can jump more than 5% soon: A 5% move from $1.78 only requires a print above $1.87. That can happen as soon as investors stop valuing Waldencast as a troubled two-brand structure and start valuing it as a post-closing cash-and-Milk stub. The catalyst is not mystical. It is balance-sheet math.

What should surprise the reader: The market reaction is treating Obagi’s sale like a partial liquidation of the good business. The disclosed numbers say something harder to ignore: even with a conservative haircut that counts only the cash portion and the fixed vendor note, the market is assigning very little value to the remaining Milk Makeup franchise.

The Setup

On June 1, 2026, Waldencast announced a definitive agreement to sell Obagi Medical to Bridgepoint in a transaction valued at up to $460 million. The company said the deal is expected to close in Q3 2026, is not subject to a financing condition or shareholder vote, and that at closing it intends to repay approximately $178 million of senior secured term debt. The same release said Milk Makeup generated $110.4 million of 2025 net revenue and $15.2 million of adjusted EBITDA. [1][2]

The stock did not behave like a company suddenly handed a clean balance-sheet reset. StockTitan’s June 1 market-reaction snapshot showed WALD at $1.78, down 2.73% on the session, implying a market capitalization of about $234.72 million. [3]

That disconnect is the entire trade. The market is focused on three uncomfortable facts: founders are leaving the public stub, part of the consideration comes through notes and earnouts rather than all cash, and the remaining company becomes a one-brand story. All true. None of that automatically justifies pricing the residual operating business so cheaply.

The Mispricing

The market appears to be pricing Waldencast as if the Obagi sale mostly plugs a debt hole and leaves behind a fragile, lower-quality residual equity.

The variant view is narrower and more defensible:

The signed sale sharply reduces leverage risk.
The market is giving too little credit to the minimum disclosed value that remains after debt repayment.
The market is pricing Milk Makeup at a multiple that looks closer to distress than to a branded beauty asset with positive EBITDA.

Facts:

Waldencast agreed to sell Obagi at up to $460 million. [1]
The disclosed structure includes $366 million of cash, a $10 million fixed vendor note, a $20 million adjustable vendor note, and up to $64 million of earnout payments. [1]
Waldencast intends to repay about $178 million of senior secured term debt at closing. [1]
Milk Makeup produced $110.4 million of 2025 revenue and $15.2 million of adjusted EBITDA. [1]
As of February 27, 2026, Waldencast had 128,259,872 ordinary shares outstanding. [2]
WALD traded at $1.78 on June 1, implying about $234.72 million of market cap. [3]

Conservative arithmetic:

Start with only the disclosed $366 million cash plus the $10 million fixed vendor note.
Ignore the $20 million adjustable vendor note.
Ignore the earnout entirely.
Subtract the planned $178 million debt repayment.

That leaves about $198 million of value before taxes, fees, working-capital adjustments, and other deal frictions. Against a $234.72 million market cap, the implied value being assigned to the remaining Milk Makeup stub is about $36.72 million. That is roughly 2.4x Milk’s 2025 adjusted EBITDA.

Inference:

Even if one applies a meaningful haircut for taxes, fees, and working-capital leakage, the residual operating-business valuation still looks compressed.

The Market Price

Instrument / Marker	Latest Level	Timestamp	Source	Read-Through
`WALD` common stock	$1.78	June 1, 2026 market-reaction snapshot, 15-minute delayed	StockTitan reaction page	Current public equity value is about $234.72 million.
`WALD` previous close	$1.23	June 1, 2026 pre-news reference on StockTitan / company-site quote context	StockTitan reaction page and Waldencast site quote context	The market repriced the story higher, but not enough to reflect a clearly de-risked stub.
Shares outstanding	128,259,872	As of February 27, 2026	Waldencast Q4 2025 / FY 2025 results	Used for market-cap math and per-share framing.
Obagi transaction value	Up to $460 million	June 1, 2026	Waldencast sale announcement / 6-K	Gross value of divested business.
Cash portion of purchase price	$366 million	June 1, 2026	Waldencast 6-K summary	Conservative base for equity-value math.
Fixed vendor note	$10 million	June 1, 2026	Waldencast 6-K summary	Included in base math because it is fixed, not contingent.
Debt to be repaid at closing	About $178 million	June 1, 2026	Waldencast sale announcement	Main balance-sheet de-risking mechanism.
Milk Makeup 2025 revenue	$110.4 million	FY 2025	Waldencast sale announcement	Shows the residual company is not a shell.
Milk Makeup 2025 adjusted EBITDA	$15.2 million	FY 2025	Waldencast sale announcement	Used for residual valuation sanity check.

The market price says investors trust the announced deleveraging only partly and heavily discount the remaining brand.

The Positioning

This is not a classic squeeze trade. It is a misclassification trade.

The likely holders after the June 1 release fall into three rough camps:

Positioning Proxy	Evidence	Interpretation
Event-driven holders	Heavy relative volume of 11.8x on StockTitan’s reaction snapshot. [3]	Fast money showed up immediately, which raises the odds that some holders are reacting to headlines rather than working through stub math.
Skeptical legacy holders	The stock fell on several positive Obagi news items earlier in 2026, according to StockTitan’s historical context summary. [3]	The market learned to fade Obagi headlines. That habit may now be contaminating a more important balance-sheet event.
Fundamental buyers	Milk’s 2025 revenue and EBITDA are disclosed, and the debt paydown path is explicit. [1][2]	The setup becomes more attractive as holders shift from narrative to pro-forma math.

Missing data:

Live short interest
Live borrow rate
Options open interest and skew
Tax leakage estimate
Net working-capital adjustment estimate

Those missing pieces matter, but they do not break the core arithmetic.

The Catalyst

Date / Window	Catalyst	Why It Matters
June 1, 2026	Definitive sale announcement	Locks in the strategic path and resets the valuation debate.
Next several trading sessions	Investor rework of stub value	The easiest near-term move is a math catch-up, not a new corporate action.
Q3 2026	Expected close of Obagi sale	Converts announced deleveraging into realized balance-sheet change.
Between signing and close	Any board disclosure on capital allocation	The residual cash and note proceeds matter because they determine how much of the post-close equity becomes true net cash versus reinvestment.

The closing mechanism is simple. The market does not need to assume heroics. It only needs to stop acting as if Milk is close to worthless after debt paydown.

The Gap

The market is pricing these claims:

Obagi was the good asset and Waldencast is selling quality to survive.
The purchase price is too contingent to support meaningful equity rerating now.
Founder departures make the residual stub structurally weaker.

The variant view:

Selling a good asset can still create equity value if the public market had been over-discounting leverage and structure.
The fixed economics already disclosed are enough to make the residual valuation look compressed.
Milk Makeup is not a worthless leftover. It is a real brand with positive EBITDA and U.S. distribution.

This thesis does not require the full $460 million. It works on a more conservative base.

The Payoff Map

This is a common-stock stub trade. It is not a merger-arb spread with a hard cash-out at the parent level. The position should be sized accordingly.

The long case is that the market lifts the stock as the residual valuation becomes easier to underwrite. The top case assumes investors give Milk a more normal brand multiple and stop treating the post-close company like a damaged orphan. The base case assumes only a partial rerating as the market credits the debt paydown and a modest value to Milk. The bottom case assumes the market decides the earnout, note structure, founder exits, and concentration risk deserve a much steeper discount.

Price Target and Probability Map

Scenario	Target Price	Probability	Return From $1.78	Contribution to Expected Return	Evidence Quality	What Has To Happen
Top case	$2.60	25%	46.1%	11.5%	Medium	Investors capitalize Milk at a meaningfully higher residual value and give partial credit to adjustable note and earnout upside.
Base case	$2.15	50%	20.8%	10.4%	Medium-high	The market credits the cash math, debt repayment, and a modest standalone value for Milk without paying up for the full contingent consideration.
Bottom case	$1.10	25%	-38.2%	-9.6%	Medium	The market decides the residual stub deserves a severe governance and concentration discount and worries that value leakage will consume most of the sale proceeds.

Probability-weighted expected return: about +12.3% before trading costs, taxes, and gap risk.

Current market price / level: WALD at $1.78.

Timestamp: June 1, 2026 market-reaction snapshot, checked June 2, 2026 at 08:01 +07.

Primary instrument: WALD common stock.

Alternative expressions considered: Options were not selected because live chain quality, open interest, and spread width were not verified during this run.

What Could Go Wrong

The strongest counterargument is the obvious one: Obagi may have been the more valuable and more defensible business, and the public stub could deserve a harsh discount because founders are leaving, proceeds are partly contingent, and Milk becomes the sole operating pillar.

That argument is serious. It is also probably overextended at $1.78 if the company really does repay about $178 million of debt and keep a positive-EBITDA brand.

Other risks:

Working-capital adjustments, fees, taxes, and vendor-note economics can reduce value meaningfully.
The earnout may never be achieved.
Founder departures can weigh on sentiment longer than arithmetic would justify.
The market may prefer clean cash realizations and refuse to rerate before the deal closes.

What Would Prove This Wrong

Invalidation Trigger	Why It Matters
The transaction is terminated or materially repriced lower.	The entire stub math changes.
New disclosures show much heavier value leakage than currently visible.	The market may be right that little residual value remains.
The company signals that most remaining proceeds will be consumed rather than retained or returned.	The post-close equity becomes less attractive.
`WALD` breaks below $1.25 on company-specific news.	That would indicate the market no longer believes the announced transaction de-risks the equity enough to support the current thesis.

Risk Audit

Strongest counterargument: Waldencast is selling the better asset and leaving public holders with a smaller, less diversified, founder-depleted beauty brand whose fair value can be much lower than bulls assume.

Most fragile assumption: Milk Makeup’s $15.2 million of adjusted EBITDA is durable enough to deserve more than a distressed multiple once the capital structure is cleaned up.

What the market may already know: The fixed cash/debt-paydown math is public and not hidden.

What could make the trade lose money even if the thesis is directionally right: The market may refuse to close the value gap until the deal actually closes, leaving the stock stuck or lower for weeks.

Liquidity / execution risks: This is still a low-priced stock with event-driven volume. Use limits. Do not chase sharp opening gaps.

Leverage risks: None should be introduced by the trader. The common stock already contains enough event risk.

Information reliability risks: The key figures come from issuer filings and a market-reaction page. Live intraday market data outside the cited snapshot was not independently verified through an exchange terminal in this run.

Invalidation trigger: Deal break, major negative revision to proceeds, or company-specific break below $1.25.

Publish / revise / reject recommendation: Publish as a long common-stock deep-dive note.

Best Trade Strategy

Field	Strategy
Direction	Long
Preferred instrument	`WALD` common stock
Common-stock stance	One possible expression is buying common stock near the June 1 reaction zone around $1.78.
Options stance	Not preferred in this run due to insufficient live option-chain verification.
Entry reference	$1.78
Take-profit / target	First trim near $2.15. Reassess near $2.60 if the market starts capitalizing Milk more normally.
Stop / invalidation	Reassess hard below $1.25 on company-specific weakness or if the transaction terms deteriorate.
Time horizon	Several days to several weeks for rerating; Q3 2026 for closing confirmation.
Execution risks	Deal adjustments, tax/fee leakage, concentration risk, founder departures, and a market that insists on waiting for close.
Do-not-trade conditions	Do not buy after an indiscriminate vertical gap without reworking the residual valuation. Do not buy if new filings materially lower the fixed-value portion of proceeds.
Monitoring checklist	New 6-K disclosures, purchase-price adjustment details, debt-paydown confirmation, any capital-allocation guidance for residual cash, and whether price holds above $1.50 and then reclaims $1.87.

Bottom Line

Waldencast is not a beauty-growth story in this setup. It is a signed asset-sale stub. The market is reacting to the emotional part of the announcement and underweighting the arithmetic. At $1.78, the stock still implies that after a major debt paydown the remaining Milk Makeup franchise deserves only a thin residual value. That is the disagreement inside the price. The trade is long common stock.

Research Quality Scorecard

Criterion	Score	Evidence Note
Market disagreement	5	Signed sale and debt-paydown math versus a still-compressed stub valuation.
Evidence base	5	Fresh June 1 filing, FY 2025 brand metrics, share count, and same-day market reaction.
Positioning and flows	4	Relative-volume evidence is useful, but live short and borrow data are missing.
Catalyst path	5	Definitive agreement now, closing expected in Q3 2026, and near-term rerating path is explicit.
Payoff architecture	4	Target map and EV are defined, though the transaction is not a pure cash-out.
Invalidation discipline	5	Clear break conditions and deal-risk triggers included.
Differentiated insight	5	The residual Milk valuation is the non-obvious piece most readers will not calculate.
Client value	5	Useful even without taking the trade because it reframes how to value the stub.
Total	38 / 40	Publish-ready under the 32+ threshold.

Sources

Source	Date / Timestamp	Use
Waldencast sale announcement / Exhibit 99.1	June 1, 2026	Obagi sale value, debt repayment plan, closing conditions, and Milk Makeup 2025 revenue / adjusted EBITDA.
Waldencast Q4 2025 and FY 2025 results	March 13, 2026	Share count as of February 27, 2026 and broader FY 2025 operating context.
Waldencast 6-K filing summary	June 1, 2026	Disclosed structure of consideration: cash, vendor notes, and earnout.
StockTitan WALD market reaction page	Checked June 2, 2026; market reaction dated June 1, 2026	Same-day price, market cap, relative volume, and reaction context.
Jasper Therapeutics June 1 strategic-review 8-K	June 1, 2026	Candidate comparison for `JSPR`.
Jasper Q1 2026 results	May 14, 2026	Candidate comparison cash balance and financing-risk evidence for `JSPR`.
IAC proposal to acquire MGM, Exhibit 99.1	June 1, 2026	Candidate comparison, bid price, premium, and ownership context for `MGM`.
Historical prices for MGM common stock	Crawled today	Candidate comparison showing stock trading above the offer zone.

Section 17 Quality Gate

Check	Answer	Note
1. Is the mispricing specific?	yes	residual Milk valuation versus signed sale and debt-paydown math.
2. Is there evidence beyond narrative?	yes	filing data, share count, and same-day price reaction.
3. Is the positioning claim supported or clearly labeled as uncertain?	yes	heavy volume is cited; missing short / borrow data are labeled missing.
4. Is there a catalyst or plausible closing mechanism?	yes	definitive agreement now and expected Q3 2026 close.
5. Is the downside case described honestly?	yes	founder exits, value leakage, and concentration risk are explicit.
6. Is the strongest counterargument included?	yes	selling the better asset and leaving a weaker stub is addressed directly.
7. Is the article useful even if the trade is not taken?	yes	it shows how to reframe branded-asset stub valuation.
8. Are all factual claims sourced or marked as unverified?	yes	sources table included; live options and short data marked missing.
9. Does the article avoid hype?	yes	no promotional framing.
10. Does the headline match the actual evidence?	yes	the article is about Obagi proceeds versus residual Milk value.
11. Does the article explain why this is the best opportunity right now?	yes	covered in Opportunity Ranking and selected-opportunity rationale.
12. Does the article explain why the asset can plausibly jump more than 5% soon?	yes	move from $1.78 to $1.87 tied to balance-sheet recognition.
13. Does the article identify what should surprise a sophisticated reader?	yes	the implied valuation of Milk after conservative adjustments.
14. Does the article include top, base, and bottom targets with probabilities that add to 100%?	yes	25% + 50% + 25% = 100%.
15. Does the main article file include its Research Quality Scorecard in a dedicated section?	yes	included above.
16. Are all reader-facing tables kept as Markdown tables in the main article file?	yes	all tables are Markdown.
17. If optional table images were explicitly requested, are they saved separately without replacing Markdown tables?	n/a	no table images were requested.
18. If the task required an illustration prompt, is it included inline in the main article file with a subtle `The Mispricing Desk` watermark requirement?	yes	included below.
19. Does the main article file include a `Best Trade Strategy` section with required fields?	yes	direction, instrument, TP, invalidation, timeline, risks, do-not-trade conditions, and monitoring checklist included.
20. If technical signals are used, are they framed as timing inputs rather than the sole thesis?	yes	price levels are only risk markers.
21. Unless geography was explicitly scoped, did the research screen U.S., Japan, broader Asia, and Europe / UK lanes?	n/a	user explicitly scoped this run to U.S. market focus and long only.
22. If the article uses Japan market as a lane or scope, was the Japan small/mid-cap <= JPY 800 preference followed?	n/a	Japan not in scope.
23. If the user requested a live Substack finish, was the post actually created or updated in Substack, and was `substack_submission_log.txt` updated immediately?	n/a	user requested local article plus commit/push only.

Illustration Prompt

Create a realistic, high-value, high-end elite editorial cover image for The Mispricing Desk about Waldencast’s Obagi divestiture. Composition: a polished beauty-industry boardroom at dusk with a dark stone conference table. In the foreground, place two luxury product worlds being separated with forensic precision: on one side, a luminous dermatologist-grade skincare bottle set labeled Obagi; on the other, a vivid, modern color-cosmetics kit labeled Milk. Between them sits a premium transaction binder stamped Definitive Agreement, a discreet card reading $366M cash, and a debt document marked $178M repaid. The emotional tension should be that the market is staring at the departing founders while missing the residual value left on the table. Mood: intelligent, restrained, expensive, slightly skeptical. Palette: obsidian, warm ivory, muted blush, brushed silver, and a narrow line of emerald light. Avoid stock-photo glamour, charts, traders, bulls, and bears. Include a subtle but clear watermark or engraved text reading The Mispricing Desk.